Lumbar Disc Arthroplasty

Policy # 00145
Original Effective Date: 01/31/2005
Current Effective Date: 09/11/2022

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Note: Cervical Disc Arthroplasty is addressed in medical policy number 00229.

When Services May Be Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

• Benefits are available in the member’s contract/certificate, and
• Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider lumbar disc arthroplasty to be eligible for coverage.**

Patient Selection Criteria
Coverage eligibility will be considered when ALL of the following criteria are met:

• Primary complaint of axial pain determined to be of discogenic origin; AND
• Symptoms for at least six (6) months, which have not responded to a multifaceted program of conservative treatment over that period of time (see Policy Guidelines section for conservative management requirement); AND
• Presence of single or dual (when using 2-level FDA-approved implant) level, advanced disc disease at L3-L4, L4-L5, or L5-S1, as documented by magnetic resonance imaging (MRI) and plain radiographs demonstrating moderate to severe degeneration of the disc with Modic changes (peridiscal bone signal above and below the disc space in question); AND
• At least moderate pain and disability ideally documented by a visual analog scale (VAS) pain score of 40 or higher (out of 100, or 4 out of 10) or with functional limitation of one or more Instrumental Activities of Daily Living (IADLs); AND
• Any underlying psychiatric disorder, such as depression, should be diagnosed and the management optimized prior to surgical intervention; AND
• Age between 18 and 60 years; AND
Lumbar Disc Arthroplasty

Policy # 00145
Original Effective Date: 01/31/2005
Current Effective Date: 09/11/2022

- Absence of symptomatic degenerative disc disease at all other lumbar levels, as documented by normal radiographs, and MRI showing no abnormalities or mild degenerative changes; AND
- Use of an FDA-approved implant for the intended level; AND
- Absence of contraindications listed below.

Note: This document addresses lumbar disc arthroplasty when performed as an elective, non-emergent procedure and not as part of the care of an acute or traumatic event.

Note: The requirement for a period of conservative treatment as a prerequisite to a surgical procedure is waived when there is evidence of progressive nerve or spinal cord compression resulting in a significant neurologic deficit, or when cauda equine syndrome or conus medullaris syndrome is present, and urgent intervention is indicated.

Note: See Policy Guidelines section for expanded description on ADL’s and IADL’s.

Contraindications to lumbar disc arthroplasty are:
- Significant facet arthropathy at the index level;
- Disease above L3-L4 or L4-L5 depending on FDA-approved levels;
- Bony lumbar spinal stenosis;
- Pars defect;
- Prior fusion at intended level
- Poorly managed psychiatric disorder
- Chronic radiculopathy (unremitting pain with predominance of leg pain symptoms greater than back pain symptoms persisting a minimum of one year)
- Clinically compromised vertebral bodies at affected level due to current or past trauma;
- Lytic spondylolisthesis or degenerative spondylolisthesis of grade greater than 1;
- Allergy or sensitivity to implant materials (cobalt, chromium, molybdenum, polyethylene, titanium);
- Presence of infection or tumor;
- Osteopenia or osteoporosis (defined as dual-energy x-ray absorptiometry [DEXA] bone density measured T-score less than or equal to -1.0).
When Services Are Considered Not Medically Necessary
The use of lumbar disc arthroplasty when patient selection criteria are not met is considered to be not medically necessary.**

Based on review of available data, the Company considers lumbar disc arthroplasty to be not medically necessary**, including but not limited to the following:

- Disc replacement at more than one spinal level (unless FDA approved for more than one level, e.g.; prodisc®! L Total Disc Replacement); OR
- Prior spine surgery of any form at the target level; OR
- Prior lumbar fusion; OR
- Isolated radicular compression syndromes, especially due to disc herniation; OR
- Hybrid lumbar total disc arthroscopy/lumbar fusion (lumbar total disc arthroplasty at one level at the same time as lumbar fusion at a different level); OR
- Arthroplasty using devices other than those which are U.S. Food and Drug Administration (FDA) approved, or use of an FDA-approved device in a manner which does not meet FDA requirements.

Policy Guidelines
Conservative management should include a combination of strategies to reduce inflammation, alleviate pain, and correct underlying dysfunction, including physical therapy AND at least ONE complementary conservative treatment strategy.

Physical therapy requirement includes ANY of the following:

- Physical therapy rendered by a qualified provider of physical therapy services; OR
- Supervised home treatment program that includes ALL of the following:
  - Participation in a patient-specific or tailored program; AND
  - Initial active instruction by MD/DO/PT with redemonstration of patient ability to perform exercises; AND
  - Compliance (documented or by clinician attestation on follow-up evaluation); OR
Lumbar Disc Arthroplasty

Policy # 00145
Original Effective Date: 01/31/2005
Current Effective Date: 09/11/2022

- Exception to the physical therapy requirement in unusual circumstances (for instance intractable pain so severe that physical therapy is not possible) when clearly documented in the medical record;

AND;

Complementary conservative treatment requirement includes ANY of the following:
- Anti-inflammatory medications and analgesics; OR
- Adjunctive medications such as nerve membrane stabilizers or muscle relaxants1; OR
- Epidural corticosteroid injection(s)1; OR
- Alternative therapies such as acupuncture, chiropractic manipulation, massage therapy, activity modification, and/or a trial period of rest (e.g., from the aggravating/contributing factors) where applicable.

1 In the absence of contraindications.

Clinical reevaluation. In most cases, reevaluation should include a physical examination. Direct contact by other methods, such as telephone communication or electronic messaging, may substitute for in-person evaluation when circumstances preclude an office visit.

Failure of conservative management requires ALL of the following:
- Patient has completed a full course of conservative management (as defined above) for the current episode of care; AND
- Worsening of or no significant improvement in signs and/or symptoms upon clinical reevaluation; AND
- More invasive forms of therapy are being considered.

Documentation of compliance with a plan of therapy that includes elements from these areas is required where conservative management is appropriate.

Activities of Daily Living (ADLs) – These activities are the basic functions required for self-care of every-day life.
- Eating
- Bathing
Lumbar Disc Arthroplasty

Policy # 00145
Original Effective Date: 01/31/2005
Current Effective Date: 09/11/2022

- Grooming
- Dressing
- Transferring
- Toileting

**Instrumental Activities of Daily Living (IADLs)** -- These are the complex skills required to successfully live independently.

- Shopping
- Meal Preparation
- Management of Medications
- Transportation
- Housework
- Using communication devices
- Handling personal finances
- Laundry

**Imaging Studies** – All imaging must be performed and read by an independent radiologist. If discrepancies should arise in the interpretation of the imaging, the radiologist report will supersede. The results of all imaging studies should correlate with the clinical findings in support of the requested procedure.

**Background/Overview**

Lumbar disc arthroplasty, also known as lumbar artificial disc surgery or total disc arthroplasty (TDA), was developed as an alternative to lumbar fusion for treatment of back pain due to severe degenerative disc disease.

The procedure is similar to lumbar interbody fusion, in that an anterior approach is required. Unlike fusion, motion at the level of disc replacement is maintained, which would seem to be advantageous in terms of preventing secondary degenerative changes and preserving spine mechanics.

**Tobacco cessation** – To reduce the risk of pseudoarthrosis, adherence to a tobacco-cessation program resulting in abstinence from tobacco for at least 6 weeks prior to spinal surgery is recommended.
FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)

Three artificial lumbar disc devices (activL, Charité, ProDisc-L) have been approved by the U.S. Food and Drug Administration (FDA) through the premarket approval process (Table 1). Production under the name Charité was stopped in 2010 and the device was withdrawn in 2012.

Because the long-term safety and effectiveness of these devices were not known when approved, approval was contingent on completion of postmarketing studies. The activL (Aesculap Implant Systems) and ProDisc-L (Synthes Spine) devices are indicated for spinal arthroplasty in skeletally mature patients with degenerative disc disease. Degenerative disc disease is defined as discogenic back pain with degeneration of the disc confirmed by patient history and radiographs. The activL device is approved for use at 1 level. Initial approval for ProDiscL was also limited to patients with disease at 1 level. In April 2020, the ProDiscL indication was expanded to include patients with disease at up to 2 consecutive levels.

Table 1. U.S. Food and Drug Administration-Approved Lumbar Artificial Disc Devices

<table>
<thead>
<tr>
<th>Device</th>
<th>Manufacturer</th>
<th>Indication</th>
<th>PMA Number</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>activL</td>
<td>Aesculap Implant Systems, LLC</td>
<td>The activL Artificial Disc (activL) is indicated for reconstruction of the disc at one level (L4-L5 or L5-S1) following single-level discectomy in skeletally mature patients with symptomatic degenerative disc disease (DDD) with no more than Grade I spondylolisthesis at the involved level. DDD is defined as discogenic back pain with degeneration of the disc confirmed by patient</td>
<td>P120024</td>
<td>06/11/2015</td>
</tr>
</tbody>
</table>
### Lumbar Disc Arthroplasty

<table>
<thead>
<tr>
<th>Policy #</th>
<th>Original Effective Date</th>
<th>Current Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>00145</td>
<td>01/31/2005</td>
<td>09/11/2022</td>
</tr>
</tbody>
</table>

** activL Artificial Disc **

- Implemented using an anterior retroperitoneal approach.
- Patients receiving the activL Artificial Disc should have failed at least 6 months of nonoperative treatment prior to implantation of the device.

** ProDisc-L Synthes Spine **

- The PRODISC-L Total Disc Replacement is indicated for spinal arthroplasty in skeletally mature patients with degenerative disc disease (DDD) at 1 or 2 contiguous intervertebral level(s) from L3-S1. DDD is defined as discogenic back pain with degeneration of the disc confirmed by patient history and radiographic studies. These DDD patients should have no more than Grade 1 spondylolisthesis at the involved level. Patients receiving the PRODISC-L Total Disc Replacement should have failed at least six months of conservative treatment prior to implantation of the device.

©2022 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Lumbar Disc Arthroplasty

Policy # 00145
Original Effective Date: 01/31/2005
Current Effective Date: 09/11/2022

<table>
<thead>
<tr>
<th>PRODISC®-L Total Disc Replacement.</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Charite Artificial Disc is indicated for spinal arthroplasty in skeletally mature patients with degenerative disc disease (DDD) at 1 level from L4-S1. DDD is defined as discogenic back pain with degeneration of the disc confirmed by patient history and radiographic studies. These DDD patients should have no more than 3 mm of spondylolisthesis at the involved level. Patients receiving the Charite Artificial Disc should have failed at least 6 months of conservative treatment prior to implantation of the CHARITE Artificial Disc.</td>
</tr>
<tr>
<td>P040006 10/26/2004 Withdrawn 1/5/2012</td>
</tr>
</tbody>
</table>

PMA: premarket approval

A number of other artificial lumbar discs are in development or available only outside of the United States:

- The INMOTION Lumbar artificial disc (DePuy Spine) is a modification of the Charité device with a change in name under the same premarket approval. The INMOTION® is not currently marketed in the United States.
- The Maverick artificial disc (Medtronic) is not marketed in the United States due to patent infringement litigation.

©2022 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Lumbar Disc Arthroplasty

Policy # 00145
Original Effective Date: 01/31/2005
Current Effective Date: 09/11/2022

- The metal-on-metal FlexiCore artificial disc (Stryker Spine) has completed the investigational device exemption trial as part of the FDA approval process and is currently being used under continued access.
- Kineflex-L (Spinal Motion) is a 3-piece, modular, metal-on-metal implant. An FDA advisory committee meeting on the Kineflex-L, scheduled in 2013, but was canceled without explanation.

FDA product code: MJO.

Rationale/Source
This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

References
Lumbar Disc Arthroplasty

Policy #  00145
Original Effective Date:  01/31/2005
Current Effective Date:  09/11/2022

<table>
<thead>
<tr>
<th>Date</th>
<th>Action Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>12/07/2004</td>
<td>Medical Director review</td>
</tr>
<tr>
<td>12/21/2004</td>
<td>Medical Policy Committee review</td>
</tr>
<tr>
<td>01/31/2005</td>
<td>Managed Care Advisory Council approval</td>
</tr>
<tr>
<td>07/07/2006</td>
<td>Format revision, including addition of FDA and or other governmental regulatory</td>
</tr>
<tr>
<td></td>
<td>approval and rationale/source. Coverage eligibility unchanged. Format revision. No</td>
</tr>
<tr>
<td></td>
<td>change to policy statement.</td>
</tr>
<tr>
<td>01/01/2007</td>
<td>Medical Director review</td>
</tr>
<tr>
<td>01/17/2007</td>
<td>Medical Policy Committee approval. Coverage eligibility unchanged.</td>
</tr>
<tr>
<td>02/13/2008</td>
<td>Medical Director review</td>
</tr>
<tr>
<td>02/20/2008</td>
<td>Medical Policy Committee approval</td>
</tr>
<tr>
<td>02/04/2009</td>
<td>Medical Director review</td>
</tr>
<tr>
<td>02/19/2009</td>
<td>Medical Policy Committee approval. No change to coverage.</td>
</tr>
<tr>
<td>02/04/2010</td>
<td>Medical Director review</td>
</tr>
<tr>
<td>02/17/2010</td>
<td>Medical Policy Committee approval. No change to coverage.</td>
</tr>
<tr>
<td>02/03/2011</td>
<td>Medical Policy Committee review</td>
</tr>
<tr>
<td>02/16/2011</td>
<td>Medical Policy Implementation Committee approval. No change to coverage.</td>
</tr>
<tr>
<td>02/02/2012</td>
<td>Medical Policy Committee review</td>
</tr>
<tr>
<td>02/15/2012</td>
<td>Medical Policy Implementation Committee approval. No change to coverage.</td>
</tr>
<tr>
<td>01/03/2013</td>
<td>Medical Policy Committee review</td>
</tr>
<tr>
<td>01/09/2013</td>
<td>Medical Policy Implementation Committee approval. No change to coverage.</td>
</tr>
<tr>
<td>01/09/2014</td>
<td>Medical Policy Committee review</td>
</tr>
<tr>
<td>01/15/2014</td>
<td>Medical Policy Implementation Committee approval. No change to coverage.</td>
</tr>
<tr>
<td>04/02/2015</td>
<td>Medical Policy Committee review</td>
</tr>
<tr>
<td>04/20/2015</td>
<td>Medical Policy Implementation Committee approval. No change to coverage.</td>
</tr>
<tr>
<td>08/03/2015</td>
<td>Coding update: ICD10 Diagnosis code section added; ICD9 Procedure code section</td>
</tr>
<tr>
<td></td>
<td>removed.</td>
</tr>
<tr>
<td>04/07/2016</td>
<td>Medical Policy Committee review</td>
</tr>
<tr>
<td>04/20/2016</td>
<td>Medical Policy Implementation Committee approval. No change to coverage.</td>
</tr>
<tr>
<td>01/01/2017</td>
<td>Coding update: Removing ICD-9 Diagnosis Codes</td>
</tr>
<tr>
<td>05/04/2017</td>
<td>Medical Policy Committee review</td>
</tr>
</tbody>
</table>
Lumbar Disc Arthroplasty

Policy # 00145
Original Effective Date: 01/31/2005
Current Effective Date: 09/11/2022

05/17/2017 Medical Policy Implementation Committee approval. No change to coverage.
07/06/2017 Medical Policy Committee review
07/19/2017 Medical Policy Implementation Committee approval. Coverage changed from investigational to eligible for coverage with criteria to adopt AIM guidelines. Adopted criterion “Age 18 to 60 years old” for lumbar artificial intervertebral disc replacement from the North American Spine Society (NASS) Coverage Policy Recommendations.
07/05/2018 Medical Policy Committee review
09/05/2019 Medical Policy Committee review
11/07/2019 Medical Policy Committee review
04/02/2020 Medical Policy Committee review
04/08/2020 Medical Policy Implementation Committee approval. Revised coverage section and policy to track AIM Guidelines. All investigational statements are now not medically necessary. Tobacco cessation moved from the Policy Guidelines section to the Background/Overview section. Reporting of symptom severity paragraph removed from the Policy Guidelines to avoid confusion with Patient Selection Criteria regarding pain intensity and functioning.
04/01/2021 Medical Policy Committee review
04/14/2021 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
05/05/2022 Medical Policy Committee review
06/02/2022 Medical Policy Committee review
06/08/2022 Medical Policy Implementation Committee approval. Title changed from “Artificial Intervertebral Disc: Lumbar Spine” to “Lumbar Disc Arthroplasty”. All
Lumbar Disc Arthroplasty

Policy # 00145
Original Effective Date: 01/31/2005
Current Effective Date: 09/11/2022

revisions track AIM Guidelines. Replaced “lumbar artificial intervertebral disc replacement” with “lumbar disc arthroplasty” in the coverage section of the policy. Added coverage criteria bullet for “Any underlying psychiatric disorder, such as depression, should be diagnosed and the management optimized prior to surgical intervention”. Added three contraindications: prior fusion at intended level, poorly managed psychiatric disorder, and chronic radiculopathy. Added “prior lumbar fusion” as not medically necessary.

12/06/2022 Coding update
Next Scheduled Review Date: 06/2023

Coding
The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2021 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

©2022 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Lumbar Disc Arthroplasty

Policy # 00145
Original Effective Date: 01/31/2005
Current Effective Date: 09/11/2022

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>0164T, 0165T, 22857, 22862, 22865</td>
</tr>
<tr>
<td></td>
<td>Delete code effective 01/01/2023: 0163T</td>
</tr>
<tr>
<td></td>
<td>Add code effective 01/01/2023: 22860</td>
</tr>
<tr>
<td>HCPCS</td>
<td>No codes</td>
</tr>
<tr>
<td>ICD-10 Diagnosis</td>
<td>M46.46-M46.47, M51.06, M51.26-M51.27, M51.34-M51.37, M51.46-M51.47, M51.86- M51.87, M51.9, M96.1</td>
</tr>
</tbody>
</table>

**Medically Necessary (or “Medical Necessity”)** - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

A. In accordance with nationally accepted standards of medical practice;
B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

**NOTICE:** If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.
Lumbar Disc Arthroplasty

Policy # 00145
Original Effective Date: 01/31/2005
Current Effective Date: 09/11/2022

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.